Abstract: [Problem to be Solved] The present invention provides a medicament for cytokine release syndrome, autoimmune-related adverse events, macrophage activation syndrome, hemophagocytic lymphohistiocytosis or Langerhans cell histiocytosis. [Means to Solve the Problem] The present invention provides a medicament for at least one selected from the group consisting of cytokine release syndrome, autoimmune-related adverse events, macrophage activation syndrome, hemophagocytic lymphohistiocytosis and Langerhans cell histiocytosis, wherein the medicament comprises a compound represented by the following formula I: or a pharmaceutically acceptable salt thereof.
Abstract: [Problem to be Solved] The present invention provides a medicament for cytokine release syndrome, autoimmune-related adverse events, macrophage activation syndrome, hemophagocytic lymphohistiocytosis or Langerhans cell histiocytosis. [Means to Solve the Problem] The present invention provides a medicament for at least one selected from the group consisting of cytokine release syndrome, autoimmune-related adverse events, macrophage activation syndrome, hemophagocytic lymphohistiocytosis and Langerhans cell histiocytosis, wherein the medicament comprises a compound represented by the following formula I: or a pharmaceutically acceptable salt thereof.
Abstract: The invention provides a method for producing a modified major mite allergen, obtained by altering a major allergen of house dust mites by gene engineering, which involve the steps of culturing prokaryotic or eukaryotic host cells transformed with a replication vector containing a gene encoding modified major mite allergen expressed from a promoter and collecting the expressed modified major mite allergen from the culture. The present invention provides a modified major mite allergen produced by the method, DNA molecules encoding same, and a pharmaceutical composition containing the modified major mite allergen.
Abstract: The present invention relates to a thrombolytic agent capable of being orally administered, said agent comprising 6-amidino-2-naphthyl 4-?(4,5-dihydro-1H-imidazole-2-yl)amino!benzoate or a pharmaceutically acceptable acid addition salt thereof.
Abstract: A solution for the preservation or perfusion of organs contains sodium lactobionate, sodium dihydrogenphosphate, raffinose, glutathione, allopurinol, nafamostat mesilate (mesylate) and optionally cyclodextrin, preferably 100-120 mM, 2-25 mM, 25-35 mM, 2-4 mM, 1-2 mM and 0.5-1 mM, respectively. The solution may be used for perfusion and storage of organs. Also disclosed are methods of use of the solution to perfuse and store organs.